BR0317880A - Modulação de funcionalidades de proteìna - Google Patents

Modulação de funcionalidades de proteìna

Info

Publication number
BR0317880A
BR0317880A BR0317880-3A BR0317880A BR0317880A BR 0317880 A BR0317880 A BR 0317880A BR 0317880 A BR0317880 A BR 0317880A BR 0317880 A BR0317880 A BR 0317880A
Authority
BR
Brazil
Prior art keywords
protein
conformation
molecules
pouch
ligand
Prior art date
Application number
BR0317880-3A
Other languages
English (en)
Inventor
David L Flynn
Peter A Petillo
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of BR0317880A publication Critical patent/BR0317880A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

"MODULAçãO DE FUNCIONALIDADES DE PROTEìNA". São providos novos processos para identificação racional de moléculas capazes de interagir com proteínas específicas ocorrendo naturalmente, a fim de render novos compostos farmacologicamente importantes e modalidades de tratamento. De modo amplo, o processo compreende as etapas de identificação de um ligante de controle de alteração que faz parte de uma proteína específica de interesse e também identificação de uma bolsa de controle de alteração complementar que faz parte de uma proteína e que interage com o ligante de controle de alteração. O ligante interage in vivo com a bolsa para regular a conformação e atividade biológica da proteína, tal que, a proteína assume a primeira conformação e uma primeira atividade biológica, mediante interação do ligante-bolsa e assume uma segunda conformação diferente e atividade biológica na ausência de interação de ligante-bolsa. Em seguida, as respectivas amostras da proteína nas primeira e segunda conformações são providas e essas são classificadas contra uma ou mais moléculas candidatas por contato das moléculas e as amostras. Dessa forma, as moléculas pequenas que se ligam à proteína na região da bolsa podem ser identificadas. São também providos novos adutos moduladores de proteína e processos para alterar a atividade da proteína.
BR0317880-3A 2002-12-31 2003-12-26 Modulação de funcionalidades de proteìna BR0317880A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US43741502P 2002-12-31 2002-12-31
US43740302P 2002-12-31 2002-12-31
US43730402P 2002-12-31 2002-12-31
US43748702P 2002-12-31 2002-12-31
US46380403P 2003-04-18 2003-04-18
US10/746,545 US20040171075A1 (en) 2002-12-31 2003-12-24 Modulation of protein functionalities
PCT/US2003/041450 WO2004061084A2 (en) 2002-12-31 2003-12-26 Modulation of protein functionalities

Publications (1)

Publication Number Publication Date
BR0317880A true BR0317880A (pt) 2005-12-13

Family

ID=32913379

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317880-3A BR0317880A (pt) 2002-12-31 2003-12-26 Modulação de funcionalidades de proteìna

Country Status (9)

Country Link
US (1) US20040171075A1 (pt)
EP (1) EP1585827A2 (pt)
JP (1) JP2006517654A (pt)
AU (1) AU2003303593B2 (pt)
BR (1) BR0317880A (pt)
CA (1) CA2511873A1 (pt)
MX (1) MXPA05007238A (pt)
TW (1) TW200506066A (pt)
WO (1) WO2004061084A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US20080220497A1 (en) * 2003-12-24 2008-09-11 Flynn Daniel L Modulation of protein functionalities
WO2006036266A1 (en) 2004-07-16 2006-04-06 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
WO2006062984A2 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
CA2589271A1 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
US20070078121A1 (en) 2004-12-23 2007-04-05 Flynn Daniel L Enzyme modulators and treatments
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
CA2678639A1 (en) * 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
BRPI0920765A2 (pt) * 2008-10-29 2015-08-18 Deciphera Pharmaceuticals Llc Amidas de cilopropano e análogos que exibem atividades anticâncer e antiproliferativas
UA114711C2 (uk) 2011-05-13 2017-07-25 Еррей Біофарма Інк. Сполуки піролідинілсечовини й піролідинілтіосечовини як інгібітори кінази trka
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
SI2922844T1 (en) 2012-11-13 2018-04-30 Array Biopharma, Inc. N-PYROLIDINYL, N'-PYRAZOLYL-WATER, TIOUREE, GVANIDINE AND CYANOGVANIDINE COMPOUNDS AS THE BLOOD KINASE INHIBITORS
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
KR102181913B1 (ko) 2012-11-13 2020-11-23 어레이 바이오파마 인크. 통증의 치료에 유용한 바이시클릭 유레아, 티오유레아, 구아니딘 및 시아노구아니딘 화합물
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US10510435B2 (en) 2013-04-30 2019-12-17 California Institute Of Technology Error correction of multiplex imaging analysis by sequential hybridization
DK2992115T3 (da) * 2013-04-30 2020-06-02 California Inst Of Techn Multipleksmærkning af molekyler ved stregkodning med sekventiel hybridisering
KR101781723B1 (ko) 2013-06-27 2017-10-23 화이자 인코포레이티드 헤테로방향족 화합물, 및 도파민 d1 리간드로서 이의 용도
US10160993B2 (en) 2014-03-21 2018-12-25 Purdue Research Foundation Tyrosine kinase biosensors and methods of use
NZ727418A (en) 2014-05-15 2023-03-31 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
CN118557737A (zh) 2018-01-31 2024-08-30 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
JP7534416B2 (ja) 2019-12-30 2024-08-14 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
ES2966336T3 (es) 2019-12-30 2024-04-22 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de cinasa amorfos y métodos de uso de las mismas
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2715155B1 (fr) * 1994-01-19 1996-07-26 Mayoly Spindler Inhibiteurs de la monoamine oxydase B et leurs procédés de préparation.
US6197599B1 (en) * 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US6410254B1 (en) * 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6500628B1 (en) * 2000-05-25 2002-12-31 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding human kinase and phosphatase homologues and uses therefor

Also Published As

Publication number Publication date
AU2003303593B2 (en) 2008-09-04
WO2004061084A8 (en) 2004-12-09
WO2004061084A2 (en) 2004-07-22
WO2004061084A3 (en) 2004-11-04
US20040171075A1 (en) 2004-09-02
TW200506066A (en) 2005-02-16
AU2003303593A1 (en) 2004-07-29
JP2006517654A (ja) 2006-07-27
MXPA05007238A (es) 2006-04-27
EP1585827A2 (en) 2005-10-19
CA2511873A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
BR0317880A (pt) Modulação de funcionalidades de proteìna
Pokhrel et al. Dynamics and selective remodeling of the DNA-binding domains of RPA
Majima et al. Translocation of loops regulates transport activity of mitochondrial ADP/ATP carrier deduced from formation of a specific intermolecular disulfide bridge catalyzed by copper-o-phenanthroline
Gakh et al. Normal and Friedreich ataxia cells express different isoforms of frataxin with complementary roles in iron-sulfur cluster assembly
Tenno et al. Structural basis for distinct roles of Lys63‐and Lys48‐linked polyubiquitin chains
Chiou et al. Nonenzymatic glycosylation of bovine lens crystallins. Effect of aging.
Kanelis et al. Solution structure of a Nedd4 WW domain–ENaC peptide complex
Villone et al. Supramolecular interactions in the dermo-epidermal junction zone: anchoring fibril-collagen VII tightly binds to banded collagen fibrils
Vlieghe et al. Crystal structure of d (GGCCAATTGG) complexed with DAPI reveals novel binding mode
WO2007008917A3 (en) Modulation of protein functionalities
McCarthy et al. Differential detergent fractionation for non-electrophoretic eukaryote cell proteomics
Karantza et al. Thermodynamic studies of the core histones: pH and ionic strength effects on the stability of the (H3− H4)/(H3− H4) 2 system
Yan et al. Fluorophore-assisted light inactivation of calmodulin involves singlet-oxygen mediated cross-linking and methionine oxidation
Suzuki et al. Crystal structures of the ATP-binding and ADP-release dwells of the V1 rotary motor
Heijnis et al. Identification of the peroxidase-generated intermolecular dityrosine cross-link in bovine α-lactalbumin
Lim et al. Using Mass Spectrometry To Study Copper− Protein Binding under Native and Non-Native Conditions: β-2-Microglobulin
Yang et al. Catalysis of the refolding of urea denatured creatine kinase by peptidyl-prolyl cis-trans isomerase
Mótyán et al. Data supporting Ni-NTA magnetic bead-based fluorescent protease assay using recombinant fusion protein substrates
BR0313151A (pt) métodos e reagentes que se relacionam à inflamação e à apoptose
Mukhopadhyay Recognition dynamics of trinuclear copper cluster and associated histidine residues through conserved or semi-conserved water molecules in human ceruloplasmin: The involvement of aspartic and glutamic acid gates
Hartman Speculations on the evolution of the genetic code II
Sahab et al. Isoelectric point-based prefractionation of proteins from crude biological samples prior to two-dimensional gel electrophoresis
Zhong et al. Two-dimensional mass spectra generated from the analysis of 15N-labeled and unlabeled peptides for efficient protein identification and de novo peptide sequencing
Murray et al. Mechanism of flavin mononucleotide cofactor binding to the Desulfovibrio vulgaris flavodoxin. 2. Evidence for cooperative conformational changes involving tryptophan 60 in the interaction between the phosphate-and ring-binding subsites
Wurm Assignment of the Ile, Leu, Val, Met and Ala methyl group resonances of the DEAD-box RNA helicase DbpA from E. coli

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.